nach oben

memo - Magazine of European Medical Oncology

Erschienen in:

30.08.2016 | comment – reprint

Developments in neuro-oncology

verfasst von: Silvia Hofer, MD

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 2/2018

Einloggen, um Zugang zu erhalten

Summary

A short statement on the most recent developments in the neuro-oncology field, including the new WHO Classification of Tumors of the Central Nervous System (2016) and current treatment strategies.

Vorheriger Artikel Pulmonary mass: never judge a book by its cover

Louis DN, Perry A, Reifenberger G, et al. The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol. 2016;131(6):803–20. doi:10.1007/s00401-016-1545-1.CrossRefPubMed

Seystahl K, Gramatzki D, Roth P, Weller M. Pharmacotherapies for the treatment of glioblastoma – current evidence and perspectives. Expert Opin Pharmacother. 2016;17(9):1259–70.CrossRefPubMed

Li X, Wu C, Chen N, et al. PI3K/Akt/mTOR signaling pathway and targeted therapy for glioblastoma. Oncotarget. 2016;7(22) doi:10.18632/oncotarget.7961.CrossRefPubMedPubMedCentral

Buckner JC, Shaw EG, Pugh SL, et al. Radiation plus procarbazine, CCNU, and vincristine in low-grade glioma. N Engl J Med. 2016;374(14):1344–55. doi:10.1056/NEJMoa1500925.CrossRefPubMedPubMedCentral

Cairncross G, Wang M, Shaw E, et al. Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. J Clin Oncol 2013;31:337–43CrossRefPubMedPubMedCentral

van den Bent MJ, Brandes AA, Taphoorn MJ, et al. Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951. J Clin Oncol. 2013;31:344–50.CrossRefPubMed

Faulkner C, Ellis HP, Shaw A, et al. BRAF fusion analysis in pilocytic astrocytomas: KIAA1549-BRAF 15-9 fusions are more frequent in the midline than within the cerebellum. J Neuropathol Exp Neurol. 2015;74(9):867–72.CrossRefPubMedPubMedCentral

Titel: Developments in neuro-oncology
verfasst von: Silvia Hofer, MD
Publikationsdatum: 30.08.2016
Verlag: Springer Vienna
Erschienen in: memo - Magazine of European Medical Oncology / Ausgabe 2/2018
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI: https://doi.org/10.1007/s12254-016-0278-0

Current and future developments of immunotherapy in lung cancer

review

Chimeric antigen receptor T‑cell therapy—a hematological success story

Open Access
short review

ASH 2017: highlights in chronic myeloid leukemia

short review

Update and clinical highlights presented at the 2017 American Society of Hematology Meeting

editorial

Acute myeloid leukemia—current data from the 2017 American Society of Hematology meeting

short review

My burning issues in aggressive Non Hodgkin’s Lymphoma

special report

Springer Medizin Österreich

Developments in neuro-oncology

Summary

Weitere Artikel der Ausgabe 2/2018

Current and future developments of immunotherapy in lung cancer

Chimeric antigen receptor T‑cell therapy—a hematological success story

ASH 2017: highlights in chronic myeloid leukemia

Update and clinical highlights presented at the 2017 American Society of Hematology Meeting

Acute myeloid leukemia—current data from the 2017 American Society of Hematology meeting

My burning issues in aggressive Non Hodgkin’s Lymphoma

Springer Medizin Österreich

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Current and future developments of immunotherapy in lung cancer

Chimeric antigen receptor T‑cell therapy—a hematological success story

ASH 2017: highlights in chronic myeloid leukemia

Update and clinical highlights presented at the 2017 American Society of Hematology Meeting

Acute myeloid leukemia—current data from the 2017 American Society of Hematology meeting

My burning issues in aggressive Non Hodgkin’s Lymphoma